cations including the purging of tumour cells in solid tumours, myeloma and lymphomas, gene marking and ex vivo expansion. [1] [2] [3] [4] [5] In these applications the CD34 + cell CD34 positive (CD34 ؉ ) cell selection is increasingly used for a number of important applications including gene purity and yield, although variable, has been about 90% and 50% respectively. ؉ cell selection in CML but these results must be confirmed using large scale clinical col-
CD34
+ cell separation was performed using MiniMACS as a percentage of CD45 + cells, and compared to isotypic control. Using CD34 V SSC a gate was set around the and Ceprate columns on three nonpaired normal BM samples. Separation of normal BM by Isolex columns was CD34-positive cell fraction, and the CD38 or HLA-DR positive and negative fraction determined on plots of CD38 not performed because of the high minimum mononuclear cell number of 2 × 10 8 required for the operation. Seven or HLA-DR V CD34. Using the same gate the pre-and negative samples were similarly analysed. Specimens were (two BM, five PB), eight (two BM, six PB) and four (four PB) nonpaired CML samples were separated using Minianalysed using a FACScan (Becton Dickinson) with CELLQuest software (Becton Dickinson). MACS, Ceprate and Isolex, respectively. CML samples have been grouped together for analysis because there were A minimum of 15 000 (positive fraction) and 50 000 (pre-separation and negative fraction) CD45
+ events were no differences between the CD34 + cell purity or yield between BM and PB. Five paired CML samples were separcounted. A minimum of 100 CD34 + events were counted within the negative sample. ated with MiniMACS and Ceprate. Paired Baxter separations were not performed because of the cell number CD34 + cell yield in the positive or negative sample was calculated by: required for the operation (see above).
% CD34
+ cells in positive fraction × total number cells in positive fraction % CD34 + cells in unseparated fraction × total number starting cells .
Columns
Cell counts were the mean of two separate counts obtained The performance of three columns was assessed by followfrom an improved Neubauer counting chamber (Weber ing the manufacturer's instructions exactly with the excepScientific, Lancing, UK). tion that the sample was applied only once, not twice, to the MiniMACS column. In the Ceprate LC column mononuclear cells were incubated with a single biotinylated CFU-GM 12.8 IgM anti-CD34 antibody and then applied to avidin-10 5 plastic adherent cell-depleted mononuclear cells (pre) coated beads contained within a column. The CD34 + fracwere plated per 1 ml CFU-GM culture in triplicate in tion was removed by gentle squeezing of the column. In methylcellulose (H4230; Stem Cell Technologies, Vanthe Isolex 50 system cells were incubated with a 9C5 mouse couver, Canada). Equivalent proportions of plastic adherent IgG1 anti-CD34 antibody followed by incubation with antidepleted positive, negative and positive + negative cells mouse coated Dynal (Dynal, Oslo, Norway) magnetic were plated for CFU-GM and colonies of greater than 200 microspheres of 4.5 m diameter and magnetic separation cells were scored at 14 days. Plastic adherent depleted cells performed within a reaction chamber. The microspheres were used to eliminate accessory cells and make pre-and were detached from the CD34 + cells by chymotrypsin and post-separation samples comparable. 17 CFU-GM results are the microspheres separated from the CD34 + cells magnetithe mean of triplicate cultures. cally. In the MiniMACS system mononuclear cells were incubated with a QBEND/10 mouse IgG1 anti-CD34 antibody followed by incubation with anti-mouse antibodyChanges to Ceprate method coated magnetic particles of Ͻ0.5 m diameter. A magLow CD34 + cell yields were obtained with the Ceprate colnetic field separation was performed through a column umn. In two replicate experiments with CML PB, changes filled with plastic-coated steel wool surrounded by an exterto the Ceprate operating method were made (after disnal magnet. The magnet was removed and the positive fraccussion with the manufacturers), in an effort to improve tion flushed through the column. Samples for analysis were yields: (1) Centrifugation before Lymphoprep separation at taken from the mononuclear cells before antibody incu-1400 r.p.m. for 10 min with the brake off in order to bation and from the positive and negative fractions followremove platelets; (2) cell dilution and washing with 4.5% ing column separation.
HSA ( + measurement was performed by the method described by Bender et al.
CD34
+ cell purities following column separation are shown in Table 1 . In five paired CML samples the mean CD34
+

Briefly, CD45
+ events were used to gate the leucocytes, which were then plotted on CD34 V SSC. Only CD34 + cell purity with the Ceprate and MiniMACS columns were 92.5 and 80.9%, respectively, P = 0.04. In each paired samevents with low SSC were used to calculate CD34 + cells ple the Ceprate purity was higher than with MiniMACS. There were no other significant differences between CD34 + cell purities. Purity did not correlate with the starting CD34 + cell number. Combining results of paired and unpaired CML samples, the CD34
+ cell yield was higher with MiniMACS (n = 7) than with Ceprate (n = 8) or Isolex (n = 4) with means of 51.1, 24.3 and 13.2%, respectively, (P = 0.04 and P = 0.01) (Figure 1a) . These results were compared with yields obtained with unpaired normal BM samples using Mini-MACS (n = 3) and Ceprate (n = 3) columns with means of 52% ± 15.8 and 61.4 ± 40.3 respectively, (P = 0.9 and P = 0.1). CD34
+ cell yields were compared with five paired CML samples using MiniMACS and Ceprate columns with yields of 58 and 19% respectively, P = 0.04 (Figure 1b ). Processing and column loss of CD34 + cells (CD34 + cells not present in the positive and negative fractions after separation) was similar between the three columns with mean losses of 16% ± 19, 20% ± 21 and 24% ± 14 for MiniMACS, Ceprate and Isolex respectively. There were no correlations between the CML CD34 + cell yield and the patients' platelet or leucocyte count or CD34 + cell percentage after lymphoprep. elet 'prespin' and 26% using ACD anticoagulation. The clonogenic potential of CD34 + cells in the precolumn sample was compared with the MiniMACS and CeprDiscussion ate column-separated positive and negative fractions ( Table 2 ). The CFU-GM plating efficiency of normal BM The separation of CD34 + cells is likely to be increasingly used for a number of important applications in CML includ-CD34 + cells was the same for the pre-and post-column fractions for both MiniMACS and Ceprate columns. The ing gene therapy, antisense oligonucleotide purging, longterm bone marrow culture and selection of cells with an plating efficiencies of the CML presample and positive fraction were similar for MiniMACS and Ceprate columns.
HLA-DR negative phenotype. 10-12 Although CD34 + cell separation is a well-established technology in other areas In both columns the negative fraction had a lower plating efficiency than the positive fraction but this did not reach of haemato-oncology 1-5 it has not been objectively assessed in CML. We have compared the technical performance of statistical significance.
The percentages of CD34 + 38 − and of CD34 + DR − cells three laboratory scale column CD34 + separation devices. Two of these columns, Ceprate and Isolex are already in before column separation and in the positive fraction following separation is shown in Table 3 . There was no sigclinical use and MiniMACS will be licensed for clinical scale separation in the near future. The performance of the nificant change in the CD34 + subpopulations following any of the methods of column CD34 + cell separation in normal MiniMACS and Ceprate columns were compared directly using the same sample, the Isolex column was assessed or CML samples.
Column CD34
؉ cell selection in CML TE Hawkins et al 412 using different samples because of the higher starting ences in column technology between avidin/biotin or magnetic field separation. This study was not designed to mononuclear cell number. All three columns gave a high CD34 + cell purity with the Ceprate column giving the highinvestigate the reasons for the differences in results, but additional studies could include using the same antibody est purity. The MiniMACS column gave the highest CD34 + yield. It is possible that a higher purity at the expense of conjugated to biotin and magnetic particles with the different columns or the same column technology with lower yield may have been achieved if the sample was applied twice to the MiniMACS column as the manufacdifferent antibodies.
There was no change in the clonogenic potential of the turers recommend. Our experience has suggested little difference in yield or purity between one or two column pass-CD34 + cells present in the positive fraction following Mini-MACS or Ceprate separation. This suggests that both separage but a potential bias is possible. Yields of CD34 + cells did not correlate with the preseparation leucocyte or platelet ation methods preserve cell function and that the measurement of CD34 + cell number is a valid method of assessing count or with the initial percentage of CD34 + cells. We were not able to improve the Ceprate yield by changing the column performance. The negative fraction appeared to have a lower clonogenic efficiency than the other fractions operating procedure.
During sample processing and column passage a mean possibly due to a qualitative difference in CD34 + cells that fail to generate day 14 CFU-GM or the cells' clonogenic 16-24% CD34 + cells were lost. Losses were inevitable with the number of washing steps involved and it is interesting potential was damaged during column passage. However, our results indicate that the proportion of primitive CD34
+ that slightly higher losses were seen with columns employing greater washing steps (Ceprate and Isolex). Colcells, the CD34
+ DR − subpopulations, were unchanged following any of the column separations. This umn CD34
+ selection needs to minimise washing steps and different antibody incubations to avoid processing losses.
suggests that the residual Philadelphia chromosome-negative subset of haematopoietic cells in CML are preserved However the major differences between column yields were in the loss of CD34 + cells in the negative fraction. This following CD34 + cell separation. 18, 19 In this study of column performance we have assessed suggests that some CD34 + cells may not have been labelled with antibody. Each separation system uses an antibody laboratory scale columns only. We cannot be certain that these results will apply to clinical scale separations in binding to a different CD34 epitope and there may be differences in antibody affinity to different CML CD34 epi-CML. However our mean CML CD34 + cell yield following Cellpro Ceprate SC (clinical grade) separations of 24.4% topes. There are no studies addressing expression of CD34 epitopes in CML and this area requires investigation. Alteris identical to the mean Ceprate LC yield in this study.
12
We cannot test the MiniMACS clinical column because it natively variations in yield and purity may be due to differ- 
